| Celebrating "A Decade of Excellence," The 10th Annual BIO Investor Forum will attract hundreds of leading investors from around the nation to San Francisco in October. They will be scheduling meetings with and hearing presentations from private and early-stage biotech companies as well as a discovery track of startup companies. Don't miss one of the only investor conferences of the year focused on early-stage companies! In addition to the opportunity for private meetings with investors, there are numerous networking events, therapeutic workshops, business roundtables, and plenary sessions offering essential knowledge for investors and biotech company executives including… For an up-to-date listing, see the Preliminary Program. Advisory Committee: John Chambers, Managing Director & Head of Healthcare
Investment Banking, Roth Capital Markets
Annette Grimaldi, Managing Director, BMO Capital Markets
James I. Healy, MD, PhD, General Partner, Sofinnova Ventures, LLC
Adam Koppel, MD, PhD, Managing Director, Brookside Capital, LLC
Ronald W. Lennox, DPhil, Founder, CHL Medical Partners, LLC
Gail Maderis, President & CEO, BayBio
Gwen A. Melincoff, Sr. Vice President, Business Development Strategic
Investment Group, Shire Pharmaceuticals, Inc.
Jeffrey M. Ostrove, PhD, President & Chief Executive Officer,
Ceregene Inc.
Andrew J. Schwab, Founder & Managing Partner, 5AM Ventures, LLC
Katya Smirnyagina, PhD, Venture Partner, Alta Partners, LLC
Samuel Wu, MD, PhD, Managing Director, MedImmune Ventures
Asish K. Xavier, PhD, Vice President, Johnson & Johnson
Development Corporation | Special Pre-Conference Event BIO Technology Transfer Symposium
October 24, 1 p.m. - 4:30 p.m.
The Palace Hotel Commercialization and Job Creation in the Biotechnology Sector:
What Does it Really Take? At a moment when the U.S. is looking to encourage technology job growth, an increasing number of public and private sector initiatives have been proposed to spur job creation. While the U.S. leads in the area of biotechnology, there is no guarantee that this competitive edge will continue. Moreover, although the U.S. generates more life science discoveries than any other single country in the world, there is a sense that many of these discoveries do not make it to the market place. Experts believe that it is through commercialization of these early-stage discoveries, that the U.S. will be able to jump start job creation. This public policy focused forum will explore such proposals and initiatives through the lens of a biotechnology innovator/entrepreneur. Leaders in state, federal and regional governments, academia, industry and non-profit philanthropic organizations will discuss how they propose to translate early-stage discoveries into jobs, products and ultimately economic growth. To attend, RSVP to Roy Zwahlen at rzwahlen@bio.org. | Hotel Information: The Palace Hotel
2 New Montgomery Street
San Francisco, CA 94105 Housing for the BIO Investor Forum is now open. To receive the discounted $309.00 single/double occupancy rate please mention that you are attending BIO Investor Forum when securing accommodations. All hotel reservations must be received by September 29, 2011, to receive the discounted rate. Click here for more information on accommodations at the Palace Hotel. Click here to register now! | View the 2010
Participating Investors Participating Companies* A&G Pharmaceutical, Inc.
Abbott Biotech Ventures
Aciont Inc.
ADVENTRX Pharmaceuticals, Inc.
Aeolus Pharmaceuticals, Inc.
Afraxis, Inc.
Allon Therapeutics Inc.
Allozyne Inc.
Anacor Pharmaceuticals, Inc.
Anaphore, Inc.
Ancora Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc.
Aradigm Corporation
Arbovax, Inc.
Bayer HealthCare Pharmaceuticals
BCO Pharma
BioCycive
BIOMEDREPORTS
BioSante Pharmaceuticals, Inc.
Biotechnology Value Fund
Bristol-Myers Squibb Company
Catabasis Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Cebix Incorporated
Cell Therapeutics
CoLucid Pharmaceuticals, Inc.
CoMentis, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Dicerna Pharmaceuticals, Inc.
DLVR Therapeutics, Inc.
DNA Therapeutics SA
EGB Advisors, LLC
EluSys Therapeutics, Inc.
Envoy Therapeutics
Epiomed Therapeutics, Inc.
Epizyme, Inc.
Esperion Therapeutics
FivePrime Therapeutics, Inc
Flexion Therapeutics
FluGen, Inc.
Genocea Biosciences
Genprex, Inc.
GenVec, Inc.
GlobeImmune, Inc.
HemaQuest Pharmaceuticals, Inc.
Heptares Therapeutics Limited
Hybrigenics
Ikaria, Inc.
Immune Design Corp.
ImmunoGenes AG
Immunovaccine Inc.
ImmusanT Inc.
Inimex Pharmaceuticals, Inc.
Intellikine
InVasc Therapeutics, Inc.
Jennerex Biotherapeutics, Inc.
KAI Pharmaceuticals, Inc.
Kiadis Pharma
KineMed, Inc.
LigoCyte Pharmaceuticals, Inc.
Lipocine Inc.
MabVax Therapeutics, Inc.
Maruho Co., Ltd.
MaxCyte, Inc.
McNicoll, Lewis & Vlak
MedImmune Ventures
Mersana Therapeutics, Inc.
MeythlGene, Inc.
Mirna Therapeutics, Inc.
Mithridion, Inc.
Molecular Templates, Inc.
MP Healthcare Venture Management, Inc.
Novo A/S
Novo Nordisk Biotech Fund
Novo Ventures
OncoMed Pharmaceuticals, Inc.
Oxford Finance LLC
Panorama Capital
Paul Capital
Peregrine Pharmaceuticals, Inc.
PharmaNeuroBoost
PLx Pharma, Inc.
Prime Equity Research
Probiodrug AG
Prosensa Therapetuics
Psyadon Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc.
Rediens, Inc.
Resverlogix Corp.
Rho Capital Partners
Rib-X Pharmaceuticals, Inc.
RRC
Salter Group
Savara, Inc.
Senesco Technologies, Inc.
Shire Pharmaceuticals Inc.
Sirius Genomics, Inc.
Sofinnova Ventures
Sorbent Therapeutics, Inc.
Spinifex Pharmaceuticals
SR One
SuppreMol, GmbH
Syntaxin Limited
Syndax Pharmaceuticals, Inc.
Syntaxin Limited
TeraDiscoveries
Tetraphase Pharmaceuticals, Inc.
The Scripps Research Institute
Tobira Therapeutics, Inc.
Tranzyme, Inc.
Trius Therapeutics
TxCELL SA
Unigene Laboratories, Inc.
VantagePoint Investment Research
Velocity Pharmaceutical Development
XOMA, LLC.
Zacks Investment Research
Zalicus Inc.
ZIOPHARM Oncology, Inc
Zymeworks, Inc.
*as of 9/14 |
No comments:
Post a Comment